Identifying Attributes of Cancer Treatments: What Do Stakeholders Consider Important?

Abstract

books, reference lists). Database search terms did not generally use validated filters for study designs; many did not use any specific search terms for burden outcomes. Formal quality assessment was only performed in half of the included studies, using a variety of published checklists. ConClusions: The variation in approaches for conducting SLRs on burden of disease may make it difficult for policymakers to compare the results of SLRs in different disease areas. Consideration of the similarities and differences between the methodologies identified in this review will be useful to inform future SLRs.

Enhancing the Value of the ASCO Value Framework

“…But qualitative research has identified disease burden, alternative available treatments, quality of evidence, and convenience as factors that are also important when considering treatments. 10 In this case, a well-established tool that can be used to structure such considerations is multicriteria decision analysis or MCDA. 11,12 The basic idea of MCDA is a simple and familiar one: decision makers can be helped to analyze complex, multi-attributed choices by comparing the options one attribute at a time, assigning scores based on each attribute, and weighting and summing the scores.…”